Transgene Aktie
0,64EUR | -0,10EUR | -13,73% |
WKN: 913048 / ISIN: FR0005175080
Personal
2020 | 2021 | 2022 | 2023 | 2024 | |
---|---|---|---|---|---|
Personal am Ende des Jahres | 165 | 167 | 167 | 158 | 0 |
Umsatz pro Mitarbeiter in Mio. EUR | 0,02 | 0,06 | 0,02 | 0,01 | 0,00 |
Bilanz (in Mio. EUR) - Aktiva
2020 | 2021 | 2022 | 2023 | 2024 | |
---|---|---|---|---|---|
Summe Umlaufvermögen | 31 | 62 | 47 | 18 | 21 |
Summe Anlagevermögen | 55 | 40 | 20 | 27 | 22 |
Summe Aktiva | 85 | 102 | 66 | 45 | 42 |
Bilanz (in Mio. EUR) - Passiva
2020 | 2021 | 2022 | 2023 | 2024 | |
---|---|---|---|---|---|
Summe Fremdkapital | 35 | 35 | 29 | 30 | 27 |
Summe Eigenkapital | 50 | 67 | 38 | 16 | 15 |
Summe Passiva | 85 | 102 | 66 | 45 | 42 |
Adresse
400, boulevard Gonthier d'Andernach, 67405 Strasbourg | |
Telefon | +33 (3) 88-27-91-00 |
Fax | +33 (3) 88-27-91-11 |
Internet | http://www.transgene.fr |
Management
Alain Mérieux
Honorary Chairman |
Alessandro Riva
Chairman & Chief Executive Officer |
Benoît Habert
Independent Director |
Carol Stuckley
Independent Director |
Christelle Schwoerer
Chief Human Resources Officer |
Christophe Ancel
VP-Pharmaceutical Operations |
Emmanuelle Dochy
Chief Medical Officer |
James Wentworth
Chief Business Officer & Vice President |
Jean-Luc Bélingard
Director |
Jean-Yves Blay
Independent Director |
John Felitti
Secretary, Vice President & General Counsel |
Lucie Larguier
CFO, Director-Corporate Communications & IR |
Marie-Yvonne Landel-Meunier
Independent Director |
Maurizio Ceppi
Chief Scientific Officer |
Maya R. Said
Independent Director |
Michel Baguenault de Puchesse
Director |
Philippe Archinard
Director |
Sandrine Flory
Director |